MENLO PARK, Calif.–(BUSINESS WIRE)–iScience Interventional (iScience, Menlo Park, CA), pioneers of site-specific therapies for anterior and posterior ocular diseases, today announced an investment by Medtronic Inc. to support rapidly expanding commercialization activities and the development of innovative drug delivery technologies for the eye. iScience Interventional is the world leader in developing minimally invasive access technologies that are used to deliver drugs, biologics, and devices to difficult to reach locations within the eye.

“iScience has the potential to change how we address a wide range of ocular diseases. The ability to deliver drugs, biologics, devices, and cell therapies directly to the site of the diseases may redefine how we manage several of the most significant sight-threatening conditions of the eye”
Medtronic, one of the world’s largest medical technology companies, is committed to advancing healthcare by investing in innovative technologies and new markets….

http://www.businesswire.com/news/home/20111011005378/en/iScience-Interventional-Receives-Investment-Accelerates-Microcatheter-Commercialization